A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

NCT00217594 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Alemtuzumab (Campath)

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)